Arne Astrup from the University of Copenhagen, Denmark, discusses a meta-analysis highlighting how the anti-obesity drug rimonabant is associated with an increased risk of depressive disorders. The meta-analysis pooled data from four randomised trials from the RIO (rimonabant in obesity) programme.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv